Oncolytics to present reovirus research results

Oncolytics Biotech will present multiple research reports on oncolytic reovirus studies at the American Society of Clinical Oncology meeting. "Reolysin," the company's proprietary formulation of the human reovirus, has been demonstrated to replicate specifically in tumor cells bearing an activated Ras pathway. Reolysin may represent a novel treatment for Ras activated tumour cells and some cellular proliferative disorders. Oncolytics release